Valuation: Evogene Ltd.

Market Cap 52.39L 0 45.54L 42.39L 38.92L 73.49L 50Cr 74.63L 5Cr 1.96Cr 25Cr 1.97Cr 1.92Cr 83Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 52.39L 0 45.54L 42.39L 38.92L 73.49L 50Cr 74.63L 5Cr 1.96Cr 25Cr 1.97Cr 1.92Cr 83Cr EV / Sales 2026 *
3.53x
EV / Sales 2027 * 2.01x
Free-Float
82.39%
Yield 2026 *
-
Yield 2027 * -
1 day+0.91%
1 week-10.37%
Current month+21.87%
1 month+16.65%
3 months-31.68%
6 months-50.21%
Current year-48.27%
1 week 151.2
Extreme 151.2
181
1 month 122.7
Extreme 122.7
194.1
Current year 115.1
Extreme 115.1
410
1 year 115.1
Extreme 115.1
478.7
3 years 115.1
Extreme 115.1
3,940
5 years 115.1
Extreme 115.1
10,430
10 years 115.1
Extreme 115.1
33,500
Manager TitleAgeSince
Chief Executive Officer 60 01/12/2004
Corporate Officer/Principal - -
Corporate Officer/Principal - 01/01/2022
Director TitleAgeSince
Director/Board Member 60 -
Director/Board Member 77 03/06/2010
Chairman 60 01/06/2021
Date Insider Type Main position Quantity % Market Cap.
18/03/26 Other

Executive/Senior Manager

40,000 0.4588%
Change 5-day change 1-year change 3-year change Capi.($)
+0.91%-10.37%-62.12%-95.94% 52.39L
-1.40%+2.59%-1.71%+11.28% 4.94TCr
-1.83%+12.31%+25.72%+4.42% 3.91TCr
-2.38%-0.69%+404.23%+615.90% 4.09TCr
-2.49%-3.65%+4.27%+46.57% 3.58TCr
-1.74%+8.42%+8.85%+48.87% 3.05TCr
-2.62%-3.68% - - 1.66TCr
-1.64%-4.95%+33.81%+125.79% 1.61TCr
-0.69%-0.27%-2.30%-34.25% 1.28TCr
-0.64%+2.65%+1.25%+8.92% 1.37TCr
Average -1.42%+4.54%+45.78%+81.29% 2.55TCr
Weighted average by Cap. -1.76%+6.72%+77.18%+129.10%

Financials

2026 *2027 *
Net sales 14.84L 0 12.9L 12.01L 11.02L 20.82L 14Cr 21.14L 1.42Cr 55.55L 7.05Cr 55.73L 54.51L 24Cr 26L 0 22.6L 21.04L 19.31L 36.47L 25Cr 37.04L 2.48Cr 97.32L 12Cr 97.65L 95.5L 41Cr
Net income -1.67Cr -0 -1.45Cr -1.35Cr -1.24Cr -2.34Cr -159.29Cr -2.38Cr -16Cr -6.25Cr -79Cr -6.27Cr -6.13Cr -265.92Cr -1.39Cr -0 -1.21Cr -1.13Cr -1.03Cr -1.95Cr -132.83Cr -1.98Cr -13Cr -5.21Cr -66Cr -5.23Cr -5.11Cr -221.75Cr
Net Debt - -
Logo Evogene Ltd.
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Employees
52
Date Price Change Volume
31/26/31 ILA 155.50 +0.91% 280
30/26/30 ILA 154.10 -2.78% 37,943
29/26/29 ILA 158.50 -1.00% 50,045
28/26/28 ILA 160.10 -6.15% 80,169
27/26/27 ILA 170.60 -1.67% 95,233

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVGN Stock